With reference to the stock exchange announcement fromSoftOx Solutions AS (SoftOx) on2 July 2021 , SoftOx has chosen to temporarily withdraw the application. The biocidal products covered by the transitional arrangement will not be affected, and a new application will be submitted by the deadline of1 July 2022 . The transitional arrangement ensures the company's presence in the market. The reason why the company chooses to withdraw the application is a desire to rework and optimize the new application so that it better suits the changed conditions that now apply. When the application was first prepared, it was based on theNorwegian Environment Agency's recommendations and guidelines, which have subsequently proved to be unclear and not applicable, as well as the later lack of coincidence between theNorwegian Environment Agency and theEU Commission's interpretations in significant areas. A new application will be submitted in accordance with the EU Biocidal Regulations by1 July 2022 . The transitional arrangement is therefore valid if a new application is submitted by this date. Furthermore, SoftOx states that the products for surface disinfection have received approval from theNorwegian Medicines Agency for use in the health care system. The company has started to deliver to Hospital Purchasing (HINAS) and other players both within and outside the health sector. For further information, please contact: Geir Almås, CEO ofSoftOx Solutions AS , or Mail: ir@soft-ox.com Phone: Front Desk: (+47) 948-59-599 AboutSoftOx Solutions AS SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian BioTech company based inOslo with the aim of helping to combat major threats to human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com
Click here for more information
© Oslo Bors ASA, source